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Background: N-methyl-D-aspartate (NMDA) receptors are regulated by several G protein-coupled receptors (GPCRs)
as well as receptor tyrosine kinases. Serotonin (5-HT) type 7 receptors are expressed throughout the brain including
the thalamus and hippocampus. Long-term (2–24 h) activation of 5-HT7 receptors promotes the expression of
neuroprotective growth factor receptors, including the platelet-derived growth factor (PDGF) β receptors which can
protect neurons against NMDA-induced neurotoxicity.
Results: In contrast to long-term activation of 5-HT7 receptors, acute (5 min) treatment of isolated hippocampal
neurons with the 5-HT7 receptor agonist 5-carboxamidotryptamine (5-CT) enhances NMDA-evoked peak currents
and this increase in peak currents is blocked by the 5-HT7 receptor antagonist, SB 269970. In hippocampal slices,
acute 5-HT7 receptor activation increases NR1 NMDA receptor subunit phosphorylation and differentially alters the
phosphorylation state of the NR2B and NR2A subunits. NMDA receptor subunit cell surface expression is also
differentially altered by 5-HT7 receptor agonists: NR2B cell surface expression is decreased whereas NR1 and NR2A
surface expression are not significantly altered.
Conclusions: In contrast to the negative regulatory effects of long-term activation of 5-HT7 receptors on NMDA
receptor signaling, acute activation of 5-HT7 receptors promotes NMDA receptor activity. These findings highlight
the potential for temporally differential regulation of NMDA receptors by the 5-HT7 receptor.
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N-methyl-D-aspartate (NMDA) receptors are tetrameric
channels composed of two NR1 and two NR2 or NR3 sub-
units [1]. In the hippocampus, most NR2 subunits are
either NR2A or NR2B [2] and there is evidence that
heterotrimeric NMDA receptors containing both NR2A
and NR2B are also present [3]. Several studies have exam-
ined the ability of serotonin (5-HT) receptors to modulate
NMDA receptor activity. For example, in isolated cortical
neurons, activation of 5-HT1A receptors inhibits NMDA
receptor currents [4] and 5-HT3 receptor activation* Correspondence: mbeazely@uwaterloo.ca
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reproduction in any medium, provided the orreduces NMDA receptor currents in cortical slices [5].
In contrast, in Xenopus oocytes, 5-HT2 receptor activa-
tion increases NMDA receptor currents [6] and in pre-
frontal cortical slices, 5-HT2A/2C agonists enhance
NMDA-evoked responses [7].
Although first identified in the suprachiasmatic nucleus,
5-HT7 receptors are expressed throughout the CNS, in-
cluding the hippocampus [8]. The effect of 5-HT7 recep-
tor ligands on NMDA-evoked currents remains unknown
however recent studies provide clear evidence for the
regulation of glutamatergic signaling by 5-HT7 receptors.
5-HT7 receptors inhibit NMDA-induced neurotransmitter
release in the dorsal raphe nucleus (DRN) and the physio-
logical role of 5-HT7 receptors in circadian rhythms istd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 5-HT7 receptor activation increases NMDA-evoked currents in isolated hippocampal neurons. A) 50 nM 5-CT was applied to
isolated CA1 hippocampal neurons for 5 min beginning at min 5 after a stable baseline of NMDA-evoked currents was established (closed circles).
For the control data, vehicle (ECF) was continuously applied for 30 min. In samples treated with the 5-HT7 receptor antagonist, SB 269970
(1 μM) was included in the bath and was present before, during, and after 5-CT application. NMDA-evoked currents were recorded every 60 s by
application of 50 μM NMDA, 0.5 μM glycine for 3 s. Recordings continued for at least 20 min after drug application. Peak currents were averaged
for 5 min prior to applying 5-CT and were compared with currents averaged for values between 26 and 30 min. Data are representative of 5–6
independent experiments for each condition. B) Sample traces from the same cell treated with 50 nM 5-CT are shown at minute 3 (black trace)
or minute 28 (gray trace). C) 5-HT7 antagonist SB269970 prevents the enhancement of INMDA by 5-CT. ** Indicates p < 0.01, one-way ANOVA
(Turkey’s post hoc comparison).
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events [9,10]. In the suprachiasmatic nucleus, glutamate
excitatory post-synaptic potentials (EPSPs) and glutamate-
induced intracellular calcium levels are both inhibited by
5-HT7 receptor activation [11,12]. Taken together, these
studies suggest that 5-HT7 receptor activation decreases
NMDA and/or glutamate receptor signaling. In con-
trast, compared to wild-type, 5-HT7 receptor knock-out
mice display a reduced induction of long-term potenti-
ation (LTP), magnitude of LTP, and hippocampus-
associated learning [13]. Therefore, although there is evi-
dence that 5-HT7 receptors negatively regulate NMDA/
glutamate signaling, deletion of 5-HT7 receptors de-
creased the magnitude of NMDA receptor-dependent
events such as LTP.
5-HT7 receptors are Gαs–coupled, although they may
couple to additional Gα isoforms including Gα12 [14,15].
Recently we identified the 5-HT7 receptor as a regulator
of platelet-derived growth factor (PDGF) β receptor ex-
pression and activity [16]. Activation of PDGFβ receptors
by PDGF-BB selectively inhibits NR2B-containing NMDA
receptor currents and this may be involved in the mechan-
ism of PDGFβ receptor-mediated neuroprotection [17].
Intriguingly, 5-HT7 receptor-induced upregulation of the
PDGFβ receptor was sufficient to protect neurons against
NMDA-induced excitotoxicity [18]. Thus, we proposed
that long-term activation of 5-HT7 receptors initiates
pathways that ultimately negatively regulate NMDA re-
ceptor signaling.
To clarify the direct effects of 5-HT7 receptor activa-
tion on NMDA receptor signaling we examined the ef-
fects of 5-HT7 receptor agonists and antagonists on
NMDA-evoked currents, NMDA receptor subunit phos-
phorylation, and subunit cell surface expression in the
hippocampus. In isolated hippocampal neurons, applica-
tion of the 5-HT7 receptor agonist, 5-CT, resulted in a
rapid and sustained increase in peak NMDA-evoked cur-
rents. 5-HT7 receptor agonist treatment also differen-
tially altered NMDA receptor subunit phosphorylation
and cell surface expression. These data, along with our
previous work, suggest a model for differential NMDA
receptor regulation by 5-HT7 receptors over the short-
and long-term.Results
Application of the 5-HT7 receptor agonist, 5-CT, to iso-
lated hippocampal neurons for 5 min increased NMDA-
evoked peak currents (Figure 1). NMDA receptor currents
were evoked once every 1 min using a 3 s exposure to
NMDA (50 μM) and glycine (0.5 μM). 5-CT was applied
in the bath continuously for 5 min after a 5-min stable
baseline recording. This application increased NMDA-
evoked currents to 142.5 ± 7.4% (n = 5) compared with
baseline, whereas NMDA-evoked currents in control
cells were stable over the recording period (95.9 ± 5.2%,
n = 6) (p < 0.01, one way ANOVA (Tukey’s post hoc
comparison), Figure 1). The 5-CT-induced increase in
NMDA-evoked currents was observed within minutes
after 5-CT application and the increase in peak currents
was sustained even after 5-CT was washed out (min 10
through 30). In addition to 5-HT7, 5-CT also activates
5-HT1 and 5-HT5 receptors [19,20]. However, the increase
in NMDA-evoked currents by 5-CT was completely
blocked by the 5-HT7 receptor-selective antagonist, SB
269970 (Figure 1).
To determine if 5-HT7 receptor activation altered
NMDA receptor subunit phosphorylation we incubated
hippocampal slices with 50 nM 5-CT in the absence or
presence of SB 269970. 5-HT7 receptors are coupled to
Gαs in several cell lines [14,21-25] and the application of
5-CT to hippocampal slices robustly increased NR1 re-
ceptor phosphorylation at the PKA phosphorylation site,
serine 897 (Table 1). 5-CT application also increased the
phosphorylation of the NR1 subunit at PKC-site serine
896 (Table 1). The increase in the PKC-site serine 896
phosphorylation was blocked by the PKC inhibitor Go
6983 (Figure 2A) and the increase in the PKA-site
serine 897 phosphorylation was blocked by the PKA in-
hibitor, H89 (Figure 2B). In Figure 1, a 5 min application
of 5-CT resulted in a sustained elevation of NMDA-
evoked currents for at least 20 min after washout. To
determine if the observed changes in NR1 subunit phos-
phorylation were similarly sustained we treated hippo-
campal slices with 5-CT for 5 min, washed the slices,
and waited an additional 20 min before homogenizing
the tissue in lysis buffer. The phosphorylation state
of both serines 896 and 897 remained significantly
Figure 2 5-CT treatment of hippocampal slices increases NR1 phosph
treated with 50 nM 5-CT in the absence or presence of 1 (micro)M Go 698
were normalized to control (vehicle-treated slices) and to total NR1. Data re
experiments. * p < 0.5 compared to vehicle, ANOVA analysis with Dunnett’s
phosphoryaltion and the β-actin loading control. B) Hippocampal slices we
for 5 min. Data represent the average and standard error of 10 independen
Dunnett’s post-test. INSET: representative Western blots showing serine 897
slices were treated with 50 nM 5-CT or 300 nM LP 12 for 5 min, the slices w
20 min before lysis. Data represent the average and standard error of 8 ind
with Dunnett’s post-test. INSET: representative Western blots showing serin
treated as in C. Data represent the average and standard error of 4 indepe
Dunnett’s post-test. INSET: representative Western blots showing serine 897





5-CT 5-CT + SB SB 269970
NR1/896, n = 8 2.07 ± 0.39** 0.91 ± 0.31 1.06 ± 0.28
NR1/897, n = 8 1.51 ± 0.13** 1.00 ± 0.39 0.95 ± 0.11
NR2A/total, n = 10 0.71 ± 0.07** 0.97 ± 0.37 0.86 ± 0.17
NR2B/1472, n = 5 2.79 ± 0.37** 1.49 ± 0.61 2.86 ± 1.33
NR2B/1252, n = 10 1.39 ± 0.49 1.50 ± 0.23 1.53 ± 0.31
NR2B/1336, n = 7 1.25 ± 0.19 1.98 ± 0.31 2.36 ± 0.36**
Hippocampal slices were treated with 50 nM 5-CT in the absence or presence
of 1 μM SB 269970 for 5 min. Changes in the phosphorylation state for each
antibody were normalized to control (vehicle-treated slices) and to total NR
subunit expression. For each experiment a β-actin antibody was used to
confirm equal loading. Data presented are the average and standard error.
* p < 0.5, ** p < 0.01, compared to vehicle.
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with 5-CT (Figure 2C, D).
As mentioned above, 5-CT will also activate 5-HT1
and 5-HT5 receptors [19,20]. To confirm that the ob-
served changes in NMDA receptor subunit phosphoryl-
ation were indeed due to the activation of the 5-HT7
receptor we incubated acutely-dissected hippocampal
slices with the 5-HT7 receptor-selective agonist, LP 12
[26], in the absence or presence of the 5-HT7 receptor
antagonists, SB 269970 and SB 258719 [27]. Similar to
5-CT, LP 12 increased NR1 receptor phosphorylation at
the PKA phosphorylation site, serine 897 (Figure 3A, C)
and this increased phosphorylation was sustained for at
least 20 min (Figure 2D). Interestingly, we observed a
larger increase in the phosphorylation of the adjacent,
PKC-phosphorylated serine 896 (Figure 3B, C). However,
the magnitude of the increase in serine 896 compared toorylation at serines 896 and 897. A) Hippocampal slices were
3 (GO) for 5 min. Increases in the phosphorylation state at serine 896
present the average and standard error of 10 independent
post-test. INSET: representative Western blots showing serine 896
re treated with 50 nM 5-CT in the absence or presence of 10 μM H89
t experiments. * p < 0.5 compared to vehicle, ANOVA analysis with
phosphoryaltion and the β-actin loading control. C) Hippocampal
ere washed and incubated in drug-free buffer for an additional
ependent experiments. * p < 0.5 compared to vehicle, ANOVA analysis
e 896 phosphoryaltion and the β-actin loading control. D) Slices were
ndent experiments. * p < 0.5 compared to vehicle, ANOVA analysis with
phosphoryaltion and the β-actin loading control.
Figure 3 5-HT7 receptor activation increases NR1 subunit
phosphorylation. A) Hippocampal slices were treated with 300 nM
LP 12 in the absence or presence of 1 μM SB 258719 for 5 min.
Increases in the phosphorylation state at serine 897 were normalized
to control (vehicle-treated slices) and to total NR1. Data represent the
average and standard error of 9 independent experiments. ** p < 0.01
LP 12 vs. vehicle, # p < 0.01 vs. LP 12 vs. LP 12 + SB 258719, * p < 0.5
compared to vehicle, ANOVA analysis with Bonferroni’s post-test.
B) Hippocampal slices were treated as in A and western blots were
performed using an anti-phospho-serine 896 antibody. Data represent
the average and standard error of 10 independent experiments.
** p < 0.01 LP 12 vs. vehicle, # p < 0.01 vs. LP 12 vs. LP 12 + SB 258719,
ANOVA analysis with Bonferroni’s post-test. C) Representative Western
blots showing serine 896 and serine 897 phosphorylation, total NR1,
and β-actin.
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ation state at serine 896. The increase in serine 896
phosphorylation was also observed for at least 20 mi-
nutes after LP 12 treatment (Figure 2C). The increased
phosphorylation by LP 12 at both sites was blocked by
the 5-HT7 receptor antagonists, SB 258719 (Figure 3)
and SB 269970 (data not shown).
Application of LP 12 also differentially affected NR2
subunit phosphorylation. While LP 12 significantly re-
duced the phosphorylation state of the NR2A subunit
(Figure 4A, B), LP 12 increased NR2B phosphorylation
at tyrosine 1472 (Figure 4C, D). However the phospho-
rylation of NR2B at other tyrosine residues, 1252 and
1336, remained unchanged, with LP 12 inducing a 0.97 ±
0.12 (n = 12) and 0.93 ± 0.11 (n = 10) fold change, re-
spectively, compared to control. The effects of LP 12 on
the phosphorylation of NR2A and NR2B-Y1472 were
both blocked by SB 258719 (Figure 4) and SB 269970
(data not shown). 5-CT treatment similarly enhanced
NR2B-Y1472 phosphorylation and decreased NR2A
phosphorylation (Table 1).
Several receptors and signaling pathways regulate
NMDA receptor subunit cell surface expression. To in-
vestigate the effects of 5-HT7 receptor agonist treatment
on the cell surface expression of the NMDA receptors
subunits we treated hippocampal slices with LP 12 in
the absence or presence of SB 258719 for 5 min. In hip-
pocampal slices LP 12 treatment did not significantly
change the cell surface expression of NR1 (0.92 ± 0.13
vs. control) and NR2A (1.05 ± 0.13 vs. control), but
NR2B cell surface expression was reduced by approxi-
mately 25% and this effect was blocked by SB 258719
(Figure 5).
Discussion
5-HT7 receptor knock-out mice display a reduced induc-
tion of LTP [13] and our finding that the acute 5-HT7 re-
ceptor activation increases NMDA-evoked currents may
contribute to our understanding of how 5-HT7 receptors
Figure 4 5-HT7 receptor activation differentially alters NR2 subunit phosphorylation. A) Hippocampal slices were treated with 300 nM LP
12 in the absence or presence of 1 μM SB 258719 for 5 min. Decreases in the phosphorylation state of NR2A were normalized to control (vehicle-
treated slices) and to total NR2A. Data represent the average and standard error of 7 independent experiments. * p < 0.05 LP 12 vs. vehicle
ANOVA analysis with Dunnett’s post-test. B) Representative Western blots using anti-phospho-pan-NR2A, NR2A, and β-actin. C) Hippocampal
slices were treated as in A. Increases in the phosphorylation state of NR2B at tyrosine 1472 were normalized to control (vehicle-treated slices) and
to total NR2B. Data represent the average and standard error of 6 independent experiments. * p < 0.05 LP 12 vs. vehicle ANOVA analysis with
Dunnett’s post-test. D) Representative Western blots using anti-phospho-Y1472-NR2B, NR2B, and β-actin.
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creases in NMDA-evoked currents may also contribute of
our understanding of how 5-HT7 receptor activation po-
tentiates bursting frequency in the CA3 hippocampal neu-
rons [28] and increases CA1 extracellular population spike
amplitude in CA1 hippocampal neurons [29]. Conversely,
there is evidence that 5-HT7 receptor agonists decrease
glutamate-induced intracellular calcium release [11] and
the amplitude of glutamate EPSPs [12]. Based on the find-
ings reported here and our previous report describing the
ability of long-term 5-HT7 receptor agonist treatment to
upregulate PDGFβ receptors [16,18], we propose that the
activation of 5-HT7 receptors may regulate NMDA recep-
tor activity via two temporally distinct pathways (Figure 6):
Acute (5 min) activation of 5-HT7 receptors increases
NMDA-evoked currents whereas long-term (2–24 h) acti-
vation of 5-HT7 receptors upregulates PDGFβ receptors,
a receptor tyrosine kinase that inhibits NMDA receptor
activity [17,18,30].
5-HT7 receptors are involved in aspects of learning
and memory associated with hippocampal function [31].
For example, 5-HT7 receptor knock-out mice displayimpaired contextual fear-conditioning [13] and display a
reduced ability to recognize new environments [32].
These and other studies have promoted interest in 5-HT7
receptors as a potential drug target in Alzheimer’s disease
and are further supported by a study demonstrating an in-
crease in memory formation by a 5-HT7 receptor agonist,
AS 19 [33]. NMDA receptors are crucial components of
learning and memory pathways in the hippocampus.
Thus, the positive linkage between 5-HT7 receptors and
NMDA receptor activity may explain how 5-HT7 recep-
tors promote learning and memory as well as their in-
volvement in LTP.
Since all three 5-HT7 receptor splice variants identi-
fied in rats are positively coupled with adenylate cyclase
and display some level of constitutive activity [8], it is
not surprising that the activation of 5-HT7 receptors in
hippocampal slices increases the phosphorylation of the
NR1 subunit at serine 897. On the NR2B subunit, tyro-
sine 1472 is required/involved in CaMKII binding and
activation [34] and this phosphorylation site is linked to
spinal pain transmission [35]. Interestingly, 5-HT7 re-
ceptors agonists promote pain after formalin injection in
Figure 5 LP 12 application results in the selective reduction of the surface expression of NR2B. A) CA1 hippocampal slices were treated
with vehicle, 300 nM LP 12, or LP 12 + 1 μM SB 258719 for 5 min. The slices were biotinylated and lysates were incubated overnight with streptavidin
beads. Data represent the average and standard error of 6 independent experiments. * p < 0.05 LP 12 vs. vehicle ANOVA analysis with Dunnett’s post-
test. B) Total lysates or biotinylated samples were blotted using antibodies against NR2B or β-actin.
Vasefi et al. Molecular Brain 2013, 6:24 Page 7 of 9
http://www.molecularbrain.com/content/6/1/24animal models [36] however others have found anti-
nociceptive effects of 5-HT7 receptors [37,38]. These
differences may be due to distinct central and peripheral
pain pathways that both contain 5-HT7 receptors.
Conclusions
In summary, we have now identified two pathways down-
stream of the 5-HT7 receptor that ultimately regulate
NMDA receptor activity/signaling (Figure 6). We have
demonstrated that the upregulation of PDGFβ receptors
by long-term treatment with 5-HT7 receptor agonists is
sufficient to protect hippocampal neurons against NMDA
excitotoxicity [16,18] whereas acute activation of 5-HT7
receptors increased NMDA-evoked currents. These find-















Figure 6 Proposed model for NMDA receptor regulation by short- an
activation of 5-HT7 receptors up regulates PDGF receptor activation and ex
The upregulation of PDGFβ receptors is sufficient to inhibit NMDA-induced
subunit expression is reduced. In contrast, acute (5 min) activation of 5-HT7
NMDA receptor subunit phosphorylation and cell surface expression. Figure5-HT7 receptors as both positive and negative regulators
of NMDA receptor signaling.
Materials and methods
Reagents and antibodies
5-CT, LP 12 (4-(2-Diphenyl)-N-(1,2,3,4-tetrahydronaph-
thalen-1-yl)-1- piperazinehexanamide hydrochloride),
and H89 were purchased from Sigma (St. Louis, MO,
USA). The 5-HT7 receptor antagonists SB 258719 ((R)-
3,N-Dimethyl-N-[1-methyl-3-(4-methylpiperidin-1-yl)
propyl]benzene sulfonamide) and SB 269970 (R-3-(2-(2-
(4-methylpiperidin-1-yl)ethyl)-pyrrolidine-1-sulfonyl)-phe-
nol as well as Go 6983 were purchased from Tocris
(Ellisville, MO, USA). Antibodies purchased from Millipore





d long-term activation of 5-HT7 receptors. Prolonged (2 to 24 h)
pression in hippocampal neurons, cortical neurons, and SH-SY5Y cells.
neuronal cell death in primary cultures. In addition, NMDA receptor
receptors increases NMDA-evoked currents and differentially regulates
modified from [18].
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NR2A, anti-NR2B, anti-phospho-1252-NR2B, anti-phospho-
1336-NR2B, and anti-phospho-1472-NR2B.
Cell isolation and whole-cell recording
CA1 neurons were isolated from hippocampal slices of
postnatal day 14–21 Wistar rats as previously described
[39]. The extracellular solution was composed of 140 mM
NaCl, 1.3 mM CaCl2, 25 mM N-2-hydroxyethylpiperazine-
N’-ethanesulfonic acid (HEPES), 33 mM glucose, 5.4 mM
KCl, and 0.5 μM tetrodotoxin, and 0.5 μM glycine, with
pH of 7.3-7.4 and osmolarity ranging from 320–330 mOsm.
Recordings were done at room temperature. The intracel-
lular solution consisted of 11 mM ethyleneglycol-bis-(α-
amino-ethyl ether) N,N’-tetra-acetic acid (EGTA) as intra-
cellular calcium chelating buffer, 10 mM HEPES, 2 mM
MgCl2, 2 mM tetraethyl ammonium chloride (TEA-Cl) to
block K + channel, 1 mM CaCl2, 140 mM CsF, and 4 mM
K2ATP. NMDA currents were evoked by rapid application
of NMDA solution delivered from a multi-barreled fast
perfusion system for 2 s every minute.
Western blot
Hippocampal slices were prepared, treated with drugs for
5 min, and homogenized chilled lysis buffer (20 mM Tris–
HCl at pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
30 mM sodium pyrophosphate, 1 mM β-glycerophosphate,
1 mM sodium orthovanadate, 0.5% SDS, and 1% triton-
X-100; supplemented with Halt Protease and Phosphat-
ase Inhibitor (Thermo, Fisher, Markham, Ontario))
prior to use. Lysates were centrifuged at 14,000 × g for
20 min at 4°C and the supernatant was collected. The
supernatant was subjected to SDS-PAGE and proteins
were transferred to nitrocellulose membranes, blocked
with 5% non-fat dry milk in Tris-buffered saline and
0.1% Tween for 1 h at room temperature or overnight
at 4°C, and incubated in primary antibodies for 1 h at
room temperature or overnight at 4°C. Membranes
were washed three times in Tris-buffered saline with
0.1% Tween-20, incubated with HRP-conjugated sec-
ondary antibodies for 1 h at room temperature, washed
again, and bound antibodies were visualized by the en-
hanced chemiluminescence using the chemiluminescent
substrate (Millipore, Etobicoke, Ontario). Images of
Western blots were taken on the Kodak 4000 MM Pro
Imaging Station, and densitometric analyses were
performed using the Kodak Molecular Imaging soft-
ware. Membranes were then stripped and reprobed with
other antibodies.
Surface biotinylation assay
Hippocampal slices were incubated for 5 min with 5-HT7
receptor agonists and antagonists. Slices were washed in
ice-cold ECF and incubated with 0.5 mg/ml Sulfo-NHS-LC-biotin (Pierce) for 30 min. The biotin reaction was
quenched by washing with 10 mM glycine. Slices were
washed twice more and homogenized in lysis buffer. Lys-
ate protein concentrations were normalized and lysates
were incubated with streptavidin beads overnight at 4°C
(Sigma). Beads were washed three times in lysis buffer and
boiled in loading buffer for 5 min before separation by
SDS-PAGE.
Statistical analysis
Statistical analysis of the data was performed using the
Prism® GraphPad program. For electrophysiology, graphs
and sample tracings were made using the Origin® pro-
gram. Significance level was set at α = 0.05. Data was an-
alyzed by one-way ANOVA or Student’s t-test where
appropriate.
Animals
All animal experiments were performed in agreement
with the guidelines of the policies on the Use of Animals
at the University of Waterloo (protocol #09-17) and the
University of Western Ontario.
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